Rituximab (MabThera) as treatment for active rheumatoid arthritis;Rituximab (MabThera) til behandling af aktiv reumatoid artritis

Ugeskrift for Laeger

Volumn 168, Issue 47, 2006, Pages 4079-4081

  El Fassi, Daniel ^b   Nielsen, Claus Henrik ^b   Bendtzen, Klaus ^a  

^a Rigshospitalet   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; CD20 ANTIGEN; METHOTREXATE; MONOCLONAL ANTIBODY; RITUXIMAB;

HUMAN; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; INFUSIONS, INTRAVENOUS;

EID: 33751431617     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (10)

1. Hansen PB, Hasselbalch HC. Rituximab. Et monoklonalt CD20-antistof - hæmatologiske indikationsområder og mulige behandlingsperspektiver inden for immuninflammatoriske sygdomme. Ugeskr Læger 2004;166:466-9.
2. Cooper N, Stasi R, Cunningham-Rundles S et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004;125:232-9.
3. Smith KG, Jones RB, Burns SM et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 2006;54:2970-82.
4. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006;6:394-403.
5. Browning JL. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 2006;5:564-76.
6. Silverman GJ, Carson DA. Roles of B cells in rheumatoid arthritis. Arthritis Res Ther 2003;5:S1-S6.
7. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
8. Emery P, Fleischmann R, Filipowicz-Sosnowska A et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebocontrolled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
9. Cohen SB, Emery P, Greenwald MW et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
10. Cambridge G, Stohl W, Leandro MJ et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006;54:723-32.